Anti-aging play Elevian raises $15M equity roundElevian Inc. raised $15 million in an equity financing led by Prime Movers Lab. Also participating were Bold Capital Partners, For Good Ventures, Kizoo Ventures, Lauder Partners, Longevity Fund,...

Long-term study of AAV gene therapy in dogs finds genome integration, clonal expansionA team led by University of Pennsylvania scientists showed in Nature Biotechnology that adeno-associated viral (AAV8 or AAV9) gene therapy corrected factor VIII...

CatalYm is targeting a lesser known immunosuppressant function of GDF15 to resensitize cancer patients to checkpoint blockade and enhance the ability of CAR T therapies to infiltrate solid tumors. The Munich-based biotech has raised €50 million...

Baylor’s engineered T cells designed to avoid immune rejection Baylor College of Medicine has granted Fate Therapeutics Inc. (NASDAQ:FATE) an exclusive license to alloimmune defense receptors, which render allogeneic cell therapies resistant to host immune...

Fountain is using an unbiased data-driven approach to identify compounds that reverse the biological process of aging, and in contrast to the traditional disease hypothesis-driven approach, the company is agnostic to indication. “Eighty percent of...

Novo Nordisk is set to deliver six clinical readouts in obesity in 2020. If successful, they could deliver Novo an opportunity to dramatically expand a mostly untapped market that could become a major future growth...

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular atrophy Increasing signaling through the embryonic isoform of the skeletal muscle-specific calcium channel CACNB1 or its downstream effector GDF5 could treat age-related muscular atrophy. Transcript levels of both proteins were...

In the latest addition to a growing roster of industry collaborations, AI company Insilico has partnered with CTFH to discover and develop two programs for triple-negative breast cancer. Insilico Medicine Inc. is eligible to receive...

Acceleron discontinued development of ACE-2494 due to the frequency of antidrug antibodies observed among healthy volunteers in a Phase I trial. Acceleron Pharma Inc. (NASDAQ:XLRN) was developing ACE-2494 as a potential treatment of neuromuscular disorders....

After setting its NASDAQ IPO terms on Monday, NGM would be valued at $975 million if it prices the offering at the midpoint of its proposed range. The valuation includes a concurrent private placement of...